Polytherapy in the preventive and acute treatment of migraine: Fundamentals for changing the approach

Expert Review of Neurotherapeutics

Volumn 6, Issue 3, 2006, Pages 283-289

  Krymchantowski, Abouch Valenty ^a   Bigal, Marcelo Eduardo ^b  

^a Headache Center of Rio   (Brazil)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Combining drugs; Migraine; Polytherapy; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DOMPERIDONE; FLUNARIZINE; INDOMETACIN; KETOROLAC; LYSINE ACETYLSALICYLATE; METOCLOPRAMIDE; NADOLOL; NAPROXEN PLUS SUMATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; PROPRANOLOL; RIZATRIPTAN; ROFECOXIB; SEROTONIN 1B AGONIST; SUMATRIPTAN; TOLFENAMIC ACID; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID;

ALLODYNIA; CLINICAL TRIAL; DOSE CALCULATION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MIGRAINE; MONOTHERAPY; NEUROTRANSMISSION; PHOTOPHOBIA; POLYPHARMACY; REVIEW; UNSPECIFIED SIDE EFFECT;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; MIGRAINE DISORDERS; RECURRENCE; SUMATRIPTAN;

EID: 33645853782     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.3.283     Document Type: Review

References (45)

1. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity and attack frequency and duration. Neurology 44(Suppl. 4), S24-S39 (1994).
2. Rasmussen BK. Epidemiology of headache. Cephalalgia 15, 45-68 (1995).
3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd edition. Cephalalgia 24(Suppl. 1), 1-160 (2004).
4. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 16, 231-238 (1996).
5. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol. Clin. 15, 1-13 (1997).
6. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N. Engl. J. Med. 346, 257-270 (2002). •• Update on migraine mechanisms and treatment.
7. Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment of migraine. In: The Headaches. 2nd Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds), Lippincott Willians & Wilkins, PA, USA, 385-389 (2000).
8. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Wolff's Headache and Other Head Pain. 7th Edition. Silberstein SD, Lipton RB, Dalessio DJ (Eds), Oxford University Press, NY, USA, 121-246 (2001).
9. Bordini CA, Arruda MA, Cicciarelli MC, Speciali JG. Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial. Arq. Neuropsiquiatr. 55(3B), 536-541 (1997).
10. Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a β-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 23, 961-962 (2003).
11. Krymchantowski AV, Hampshire F. Polytherapy in migraine prevention. Clinical experience with the combination of a β-blocker plus a tricyclic antidepressant plus a calcium channel blocker. Headache 44, 499-500 (2004).
12. Headache Classification Committee Of The International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl. 7), 1-96 (1988).
13. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised criteria. Neurology 47, 871-875 (1996).
14. Dodick DW. Acute and prophylactic management of migraine. Clin. Cornerstone 4, 36-52 (2001).
15. Ferrari MD, Haan J. Drug treatment of migraine attacks. In: Headache. Blue Books of Practical Neurology. Goadsby P, Silberstein SD (Eds), Butterworth-Heinemann, MA, USA, 117-130 (1997).
16. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41, 638-645 (2001).
17. Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 38, 18-22 (1998). • Initially suggested that monotherapy may not be the most efficacious way of treating patients.
18. Bates D, Ashford E, Dawson R et al. Subcutaneous sumatriptan during the migraine aura. Neurology 44, 1587-1592 (1994).
19. Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan - nonresponders: a survey in 366 migraine patients. Headache 36, 471-475 (1996).
20. Dahlof CG. How does sumatriptan perform in clinical practice? Cephalalgia 15(Suppl. 15), 21-28 (1995).
21. Visser WH, de Vriend RH, Jaspers WM, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47, 46-51 (1996).
22. Saxena P, Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds), Lippincott Williams & Wilkins, PA, USA, 411-438 (2000).
23. Tfelt-Hansen P, McEwen J. Nonsteroidal anti-inflammatory drugs in the acute treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds), Lippincott Williams & Wilkins, PA, USA, 391-397 (2000).
24. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 42(Suppl. 1), 3-9 (2002). •• Guides physicians with regard to what patients want and expect from treatment.
25. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22, 309-312 (2002).
26. Ferrari MD, James MH, Bates D et al. Oral sumatriptan: possible benefit of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 14, 330-338 (1994).
27. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol. 55, 19-26 (2004).
28. Lance JW, Headache. Ann. Neurol. 10, 1-10 (1981).
29. Wilkinson M. Treatment of the acute migraine attack - current status. Cephalalgia 3, 61-67 (1983).
30. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus metoclopramide in the acute treatment of migraine. Eur. Neurol. 32, 177-184 (1992).
31. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346, 923-926 (1995).
32. Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 25, 776-787 (2005).
33. Goldstein J, Silberstein SD, Saper JR et al. Acetaminophen, aspirin, and caffeine versus sumatriptan in the early treatment of migraine: results from the ASSET trial. Headache 45, 973-982 (2005).
34. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq. Neuropsiquiatr. 58(2-B), 428-430 (2000). • First study suggesting the advantages of this type of combination.
35. Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander J. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 45, 983-991 (2005).
36. Krymchantowski AV, Bigal ME, Moreira PF. Rizatriptan vs. rizatriptan plus rofecoxib vs. rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol. 28(4), 10 (2004).
37. Burstein R, Levy D, Collins B, Jakubowski M. Therapeutic approach to migraine with allodynia. Neurology 64(Suppl. 1), (2005) (Abstract 151).
38. Krymchantowski AV, Bigal ME, Moreira PF. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Neurology 64(Suppl 1), (2005) (Abstract 348).
39. Brandes J, O'Carroll PC, Mannix L, Lener SE, Littlefield D, Alexander WJ. Therapeutic clinical benefits of a new single-tablet formulation of sumatriptan formulated with RT technology and naproxen sodium. Cephalalgia 25, 860 (2005).
40. Pascual J, Lainez M, Leira R. Bending the rule of monotherapy for migraine prevention? Headache 45, 748-750 (2005).
41. Krymchantowski AV. Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurol. 28(4), 1-4 (2004). • Suggests the advantages of combining different classes of drugs for migraine.
42. Ramadan NM. Targeting therapy for migraine: what to treat? Neurology 64, S4-S8 (2005).
43. Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology 64, S9-S15 (2005).
44. Burstein R, Jakubowski M. Implications of multimechanism therapy: when to treat? Neurology 64, S16-S20 (2005).
45. Fox AW, Kori SH. Pharmacokinetic opportunities for combination therapy in migraine. Neurology 64, S21-S25 (2005). •• The advantages of using combined drugs for prophylaxis.